Get started
Author

Patrick Migambi

Observed names: P. MIGAMBI, P. Migambi
ORCID: 0000-0003-4344-2872
Observed ORCID: 0000-0003-4344-2872
OpenAlex ID: A5055461864
Prevalence and drivers of false-positive rifampicin-resistant Xpert MTB/RIF results: a prospective observational study in Rwanda
2020 · Jean Claude Semuto Ngabonziza, Tom Decroo, et al. · The Lancet Microbe · 65
PDF
Reduction of diagnostic and treatment delays reduces rifampicin-resistant tuberculosis mortality in Rwanda
2020 · J-C. S. Ngabonziza, Y. M. Habimana, et al. · The International Journal of Tuberculosis and Lung Disease · 43
Prevalence of tuberculosis in Rwanda: Results of the first nationwide survey in 2012 yielded important lessons for TB control
2020 · Patrick Migambi, Michel Gasana, et al. · PLoS ONE · 21
PDF
Paucibacillary Tuberculosis Drives the Low Positive Predictive Value of Xpert MTB/RIF Ultra for Rifampicin Resistance Detection in Low-Prevalence Settings
2025 · Isabel Cuella-Martin, Francois Hakizayezu, et al. · Clinical Infectious Diseases · 16
Multidrug-resistant tuberculosis control in Rwanda overcomes a successful clone that causes most disease over a quarter century
2022 · Jean Claude S. Ngabonziza, Leen Rigouts, et al. · Journal of Clinical Tuberculosis and Other Mycobacterial Diseases · 12
PDF
Predictors of Rifampicin-Resistant Tuberculosis Mortality among HIV-Coinfected Patients in Rwanda
2021 · Dominique Savio Habimana, Jean Claude Semuto Ngabonziza, et al. · American Journal of Tropical Medicine and Hygiene · 11
PDF
CD4+ regulatory T cells and CD4+ activated T cells in new active and relapse tuberculosis
2019 · Pacifique Ndishimye, Fathiah Zakham, et al. · Cellular and Molecular Biology · 8
PDF
Implementation and evaluation of a community health workers-led digital integrated diseases screening system to provide healthcare for patients at community level in Rwanda
2026 · Jean Claude Semuto Ngabonziza, Khairunisa Suleiman, et al. · EBioMedicine · 7
Continuous surveillance of drug-resistant TB burden in Rwanda: a retrospective cross-sectional study
2022 · Yves Habimana-Mucyo, Augustin Dushime, et al. · International Health · 7
PDF
Case Report: Dynamics of Acquired Fluoroquinolone Resistance under Standardized Short-Course Treatment of Multidrug-Resistant Tuberculosis
2020 · Jean Claude Semuto Ngabonziza, Armand Van Deun, et al. · American Journal of Tropical Medicine and Hygiene · 7
PDF
Prevalence and factors associated with sputum smear non-conversion after two months of tuberculosis treatment among smear-positive pulmonary tuberculosis patients in Rwanda: a cross-sectional study
2023 · Gaetan Gatete, Kato J Njunwa, et al. · BMC Infectious Diseases · 5
PDF
Pooling sputum samples for TB testing using Xpert MTB/RIF Ultra: an innovative cost-effective and efficient approach to enhance access, equity, and coverage of TB-care among poor communities at risk
2025 · Francois Hakizayezu, Nouh Saad Mohamed, et al. · Mycobacteria · 2
PDF
High-dose amikacin in the first week of all-oral rifampicin-resistant TB treatment is safe: a single-arm trial
2025 · J. Snobre, J. Gasana, et al. · IJTLD OPEN · 2
Analyzing Satellite Imagery to Target Tuberculosis Control Interventions in Densely Urbanized Areas of Kigali, Rwanda: Cross-Sectional Pilot Study
2025 · Mauro Faccin, Caspar Geenen, et al. · JMIR Public Health and Surveillance · 2
PDF
Assessment of factors associated with Tobacco smoking among patients with pulmonary TB attending health facilities in Rwanda: A case control study
2021 · Patrick Migambi, Augustin Dushime, et al. · Research Square · 2
PDF
Epidemiology and outcomes of multidrug-resistant tuberculosis in Rwanda
2025 · J. NTWARI, R. NDIAYE, et al. · Infectious Diseases Now · 1
Determinants of TB/HIV coinfection-related deaths audited using the TB death checklist from health facilities in Rwanda
2025 · G. Mutembayire, A. Munyanshongore, et al. · Rwanda medical journal · 1
PDF
Safety of high-dose amikacin in the first week of all-oral rifampicin-resistant tuberculosis treatment for the prevention of acquired resistance (STAKE): protocol for a single-arm clinical trial
2024 · Jihad Snobre, Joel Gasana, et al. · BMJ Open · 1
PDF
Spatial clustering and transmission networks of multidrug-resistant tuberculosis in Rwanda: a national retrospective genomic and spatial epidemiological study
2026 · Isabel Cuella-Martin, Francois Hakizayezu, et al. · BMJ Open
Survival and risk factors of mortality among patients with TB/HIV coinfection in Kigali City, Rwanda: a retrospective cohort study (2019–2024)
2026 · Didier Ndabana, Solange Nikwigize, et al. · BMC Infectious Diseases
Key operational challenges at a programmatic level to achieve optimal use of the GeneXpert platform
2026 · I. Cuella-Martin, F. Hakizayezu, et al. · IJTLD OPEN
Tracking cross-border transmission of Rwanda’s successful dominant rifampicin-resistant Mycobacterium tuberculosis clone using genomic markers
2026 · Isabel Cuella-Martin, Wim Mulders, et al. · medRxiv
PDF
Caractéristiques de la tuberculose résistante au Rwanda : une analyse rétrospective nationale 2019-2023
2024 · J. Ntwari, Y. Habimana, et al. · Médecine et Maladies Infectieuses Formation
Prevalence and determinants of unsuccessful tuberculosis treatment outcome among drug-susceptible tuberculosis patients in Rwanda
2023 · Gaetan Gatete, Hinda Ruton, et al. · Research Square
PDF
Management of falsepositive rifampicin resistant Xpert MTB/RIF – Authors' reply
2020 · Jean Claude Semuto Ngabonziza, Tom Decroo, et al. · The Lancet Microbe
Works count: 25
Citation count: 213
H-index: 7
I10-index: 6
Year
Topic
Type